MY190393A - Ophthalmic composition - Google Patents

Ophthalmic composition

Info

Publication number
MY190393A
MY190393A MYPI2017001274A MYPI2017001274A MY190393A MY 190393 A MY190393 A MY 190393A MY PI2017001274 A MYPI2017001274 A MY PI2017001274A MY PI2017001274 A MYPI2017001274 A MY PI2017001274A MY 190393 A MY190393 A MY 190393A
Authority
MY
Malaysia
Prior art keywords
ophthalmic composition
salt
hyaluronic acid
ophthalmic
chlorhexidines
Prior art date
Application number
MYPI2017001274A
Inventor
Takanori Ohno
Masahiro Kawahata
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of MY190393A publication Critical patent/MY190393A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention addresses the problem of maintaining a high retention rate of the kinematic viscosity of an ophthalmic composition, such as an ophthalmic solution comprising hyaluronic acid or a salt thereof. Provided is an ophthalmic composition comprising 0.001-0.5% (w/v) of hyaluronic acid or a salt thereof, 0.0005-0.02% (w/v) of chlorhexidines, 0.03-1.5% (w/v) of propylene glycol, and 0.015% (w/v) or less of ethylenediaminetetraacetates. (no suitable figure)
MYPI2017001274A 2015-03-06 2016-03-04 Ophthalmic composition MY190393A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015045065 2015-03-06
PCT/JP2016/056861 WO2016143708A1 (en) 2015-03-06 2016-03-04 Ophthalmic composition

Publications (1)

Publication Number Publication Date
MY190393A true MY190393A (en) 2022-04-20

Family

ID=56880167

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2017001274A MY190393A (en) 2015-03-06 2016-03-04 Ophthalmic composition

Country Status (7)

Country Link
JP (2) JP6716293B2 (en)
KR (1) KR102607126B1 (en)
MY (1) MY190393A (en)
PH (1) PH12017501567A1 (en)
SG (2) SG10201901426WA (en)
TW (2) TWI745287B (en)
WO (1) WO2016143708A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3871682A1 (en) * 2016-10-14 2021-09-01 i.com Medical GmbH Method for establishing, restoring, and preserving homeostasis of the ocular surface
JP6603785B2 (en) * 2017-12-08 2019-11-06 千寿製薬株式会社 Aqueous solution containing water-soluble polymer
JPWO2021132609A1 (en) * 2019-12-27 2021-07-01
CN112870216A (en) * 2021-01-29 2021-06-01 张宽才 Pharmaceutical composition, preparation and application
JP2023022569A (en) * 2021-08-03 2023-02-15 小林製薬株式会社 Eyewash composition
CN114391550B (en) * 2022-01-06 2022-11-22 江南大学 Water-soluble chlorhexidine antibacterial agent and preparation method and application thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1072376A (en) * 1996-09-02 1998-03-17 Ofutekusu:Kk Eye drop aqueous solution comprising hyaluronic acid
JPH1160505A (en) * 1997-05-20 1999-03-02 Senju Pharmaceut Co Ltd Antiseptic composition
JPH115744A (en) * 1997-06-16 1999-01-12 Toa Yakuhin Kk Aqueous solution preparation for external use containing hyaluronic acid
JP2002193815A (en) * 2000-12-25 2002-07-10 Ophtecs Corp Eye drops for prevention of corneal drying for ophthalmic operation
JP2003002837A (en) * 2001-06-21 2003-01-08 Lion Corp Composition for aqueous skin care preparation and method for preventing clouding of liquid composition
JP4431817B2 (en) 2002-03-08 2010-03-17 第一三共株式会社 Eye drops containing tetrazole derivatives
JP4694773B2 (en) * 2003-06-06 2011-06-08 ロート製薬株式会社 Mucosal liquid composition
US20060040894A1 (en) * 2004-08-13 2006-02-23 Angiotech International Ag Compositions and methods using hyaluronic acid
RU2445950C2 (en) 2006-10-26 2012-03-27 Сэндзю Фармасьютикал Ко., Лтд. Liquid aqueous ophthalmic composition
JP5595206B2 (en) * 2009-09-30 2014-09-24 ロート製薬株式会社 Ophthalmic liquid composition
TW201309306A (en) * 2011-06-23 2013-03-01 參天製藥股份有限公司 Ophthalmic solution containing hyaluronic acid or salt thereof and propylene glycol

Also Published As

Publication number Publication date
KR102607126B1 (en) 2023-11-27
JP2020138979A (en) 2020-09-03
SG10201901426WA (en) 2019-03-28
KR20170122773A (en) 2017-11-06
TW202114648A (en) 2021-04-16
SG11201707117SA (en) 2017-10-30
TW201705948A (en) 2017-02-16
PH12017501567A1 (en) 2018-02-05
JP2016166195A (en) 2016-09-15
TWI745287B (en) 2021-11-11
JP6716293B2 (en) 2020-07-01
WO2016143708A1 (en) 2016-09-15

Similar Documents

Publication Publication Date Title
SG10201901426WA (en) Ophthalmic composition
WO2018195397A3 (en) Indole ahr inhibitors and uses thereof
SG10201908839QA (en) 2,4-dihydroxy-nicotinamides as apj agonists
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
PH12017500367B1 (en) Compounds that inhibit mcl-1 protein
AU2017228405A8 (en) Small molecule IRE1-alpha inhibitors
SG11201804121RA (en) Novel biphenyl compound or salt thereof
MX2022001291A (en) Stereochemically enriched compositions for delivery of nucleic acids.
TN2017000524A1 (en) New bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them
MX2018011194A (en) 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists.
MX2020006612A (en) Compound functioning as bromodomain protein inhibitor, and composition.
MX2018010788A (en) Ophthalmological composition.
MX2016015565A (en) Certain protein kinase inhibitors.
WO2016044463A3 (en) Mk2 inhibitors and uses thereof
PH12017501539A1 (en) Disacetoxytubulysin h and analogs thereof
MX2020001793A (en) Ahr inhibitors and uses thereof.
MX2018003554A (en) Isoxazoline-substituted benzamides and analogues as insecticides.
JOP20200323A1 (en) Methods of manufacturing amino acid compositions
MX2017016517A (en) Storage stable compositions and methods for the treatment of refractive errors of the eye.
CR20200275A (en) Hydroxyisoxazolines and derivatives thereof
WO2019078968A3 (en) Cyclic compounds as immunomodulating agents
WO2016176620A8 (en) Extracellular matrix compositions for the treatment of cancer or immunological diseases
PH12019500198A1 (en) Compounds and compositions and uses thereof
TN2017000342A1 (en) Novel cyclopropabenzofuranyl pyridopyrazinediones
WO2016164295A3 (en) Fused pyridines as adaptor associated kinase 1 (aak1) inhibitors